CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced that its newest coronary heart disease test, PrecisionCHD™, will be presented at the American College of Cardiology’s 72nd Annual Scientific Session (ACC.23), taking place in New Orleans, LA, from March 4-6, 2023.
PrecisionCHD, the company’s coronary heart disease early detection test using epigenetics, genetics, and artificial intelligence, will make its debut, including Actionable Clinical Intelligence™, a platform for healthcare providers connecting the underlying DNA methylation and single nucleotide polymorphism biomarkers measured by this test to coronary heart disease (CHD).
“This is an important step in our fight to reduce the global and national heart disease burden. Our presence at ACC this year underscores our continued progress in advancing the current paradigms to better detect and treat cardiovascular disease,” said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics. “We look forward to sharing how the insights from PrecisionCHD can drive value for patients, healthcare providers, payers, and strategic partners.”
Current methods for detecting coronary heart disease are burdensome, expensive, and require significant preparation from patients and providers. Robert Philibert, MD Ph.D., Cardio Diagnostics’ Chief Medical Officer and Co-Founder, said, “the amount of time it takes for my patients to get tested for CHD is longer than I’d like - in some cases, weeks or months. With PrecisionCHD, I can ensure that all of my patients have an easily accessible, rapid, and highly sensitive coronary heart disease assessment without the risk of radiation exposure or reactions to contrast dye.”
The company’s executive team will be onsite to showcase through an interactive demo its precision cardiovascular tests that can help improve patients’ lives and to meet with industry partners and investors. Please email Khullani@cardiodiagnosticsinc.com to schedule a meeting.
About Cardio Diagnostics
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for enabling improved prevention, early detection, and assists in the treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com.
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "should," "believe," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements include, without limitation, the Company’s expectations with respect to future performance, development and commercialization of products and services, the potential benefits and impact of the Company’s products and services, potential regulatory approvals, and the size and potential growth of current or future markets for the Company’s products and services. Forward-looking statements are statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties that could cause the actual results to differ materially from the expected results. These statements are based on various assumptions, whether or not identified in this press release, and are not intended to serve as, and they must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company’s product development and commercialization activities, including the degree that Epi+Gen CHD™ and Precision CHD™ tests are accepted and adopted by patients, healthcare professionals and participants in other key channels; the impact of COVID-19 on the Company’s business; economic conditions, dependence on management, dilution to stockholders, lack of capital, changes in laws or regulations, the effects of rapid growth upon the Company and the ability of management to execute our growth strategy and ability to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. Such factors could materially adversely affect the Company’s financial performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed within this press release.
